Tsuzuki S, Nakanishi S, Tamaki M, Oshiro T, et al. Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer. PLoS One 2021;16:e0258160.
PMID: 34597353